Delta-like protein 3 (DLL3) is an inhibitory protein.1 The Notch pathway is critical for the development and regulation of neuroendocrine versus epithelial cell differentiation in the lungs. DLL3 is typically located in the Golgi apparatus, where it inhibits Notch 1 signaling.2

In high-grade neuroendocrine tumors—including small cell lung cancer (SCLC)—DLL3 is highly upregulated and aberrantly expressed on the cell surface, with absent or rare expression on nonmalignant cells.2,3 This makes DLL3 an attractive potential novel target for investigating a BiTE® immuno-oncology molecule aimed at neuroendocrine tumors such as SCLC.

Learn more about modalities targeting DLL3:
HLE BiTE® technology, CAR T cell.

Download a brochure on DLL3, a potential target in lung cancer and other neuroendocrine tumors.


Search our clinical trials.

Visit our resources section for additional information on potential oncogenic targets.


1. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Nat Rev Clin Oncol. 2017;14(9):549-561. 2. Saunders LR, Bankovich AJ, Anderson WC, et al. Sci Transl Med. 2015;7(302):302ra136. doi:10.1126/scitranslmed.aac9459. 3. Kunninmalaiyaan M, Chen H. Oncologist. 2007;12(5):535-542.